# US 8,278,056 B2 · Detection of early stages and late stages HPV infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,056 B2
- Document ID: US8278056B2
- Status: Granted
- Kind: B2
- Application number: 12/456,076
- Filed: 2009-06-10
- Published: 2010-01-14
- Granted: 2012-10-02
- Earliest claimed: 2008-06-13
- Assignees: OncoHealth Corp.
- Inventors: Shuling Cheng
- Web page: https://patentgrep.com/patent/US8278056B2

## CPC

- G01N 33/56983: {Viruses}
- C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
- C12Q 1/708: {for papilloma}
- G01N 33/571: for venereal disease, e.g. syphilis, gonorrhoea {(herpes G01N33/56994; chlamydia G01N33/56927)}
- G01N 2333/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. Various specific or pan monoclonal antibodies recognizing specific epitope for specific HPV protein or HPV type, or common epitope for various HPV proteins or HPV types are obtained. The invention also provides one or more solid surface to coat the testing cell lysate. Also, the anti-HPV antibody can be coated on the solid surface of the invention to capture HPV proteins and detect HPV infection.

## Claims

### Claim 1

A method of detecting a papillomavirus protein in a human subject, comprising:
preparing a cell lysate solution using a sample of cells from the human subject, wherein the sample of cells comprises epithelial cells;
coating a portion of a solid surface with a first coat of the cell lysate solution;
reacting the cell lysate solution with an anti-HPV monoclonal antibody, wherein the monoclonal antibody specifically binds to a native HPV E7 protein or a native HPV E6 protein from more than one papillomavirus type, and is capable of binding in situ to the protein in a clinical sample;
forming a complex of the papillomavirus proteins HPV E6 or E7 with the antibody on the portion of the solid surface;
detecting the complex on the portion of the solid surface, wherein presence of the complex indicates presence of the papillomavirus protein present in the human subject; and
determining disease stage associated with papillomavirus infection in the human subject based at least in part on the presence of the complex, wherein the presence of the complex indicates the disease stage as a late dysplasia stage.

### Claim 2 (depends on 1)

The method of claim 1, wherein the solid surface is selected from a group that comprises a surface of a bead, a surface of a strip, a surface of a rapid test strip, a surface of a membrane, a membrane surface of a vertical flow through device, a surface of a microfluidic device, a surface of a blot membrane, a surface of a protein chip, a glass surface, and a bottom surface of a microtiter plate.

### Claim 3 (depends on 1)

The method of claim 1, wherein
the solid surface comprises a surface of a bead;
the complex is on the portion of the surface of the bead; and
the presence of the complex is detected by using FACS (Fluorescence-activated cell sorting).

### Claim 4 (depends on 1)

The method of claims 1, wherein
the solid surface comprises a surface of a rapid test strip, wherein
the antibody is immobilized on a first end of the rapid test strip;
a second antibody and the cell lysate solution are added onto a second end of the rapid test strip before flowing laterally on the surface of the rapid test strip; and
the complex of the papillomavirus with the antibody is formed.

### Claim 5 (depends on 1)

The method of claim 1, wherein
the solid surface comprises a membrane surface of a vertical flow-through device, wherein
the antibody is immobilized on the solid surface;
the cell lysate solution and a second antibody are added sequentially onto the solid surface; and
the complex of the papillomavirus with the antibody is formed.

### Claim 6 (depends on 1)

The method of claim 1, wherein the solid surface comprises a surface of a microfluidic device.

### Claim 7 (depends on 1)

The method of claim 1, wherein the papillomavirus protein in the cell lysate solution is coated on the portion of the solid surface before reacting with the antibody.

### Claim 8 (depends on 7)

The method of claim 7, wherein the papillomavirus protein is coated on a surface of a blot membrane.

### Claim 9 (depends on 7)

The method of claim 7, wherein the papillomavirus protein is coated on a bottom surface of a microtiter plate.

### Claim 10 (depends on 1)

The method of claim 1, wherein the antibody is coated on the solid surface before coating the portion of the solid surface with the first coat of the cell lysate solution.

### Claim 11 (depends on 10)

The method of claim 10, wherein the antibody is coated on a surface of a protein chip before reacting with the papillomavirus protein in the cell lysate solution.

### Claim 12 (depends on 10)

The method of claim 10, wherein the antibody is coated on a surface of a microfluidic device before reacting with the papillomavirus protein in the cell lysate solution.

### Claim 13 (depends on 1)

The method of claim 1, wherein detecting the complex on the portion of the solid surface further comprises
detecting presence of a detection agent pre-labeled on a molecule that is selected from a group comprising the antibody, the papillomavirus protein in the cell lysate solution, a secondary antibody that binds to the antibody, and a second antibody different from the antibody, wherein
the second antibody specifically binds to the papillomavirus protein from one or more papillomavirus types in the sample of cells from the human subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein the presence of the detection agent is detected by an assay, wherein
the assay is selected from a group that comprises a direct qualitative visualization of the color change of the agent, a readout by an ELISA reader, a readout by a microarray scanner, a readout by a fluorescent reader, and a readout by a FACS (Fluorescence-activated cell sorting) instrument.

### Claim 15 (depends on 1)

The method of claim 1, further comprising
coating the portion of the solid surface with an antibody for a cellular protein and
comparing presence of the cellular protein with the presence of the papillomavirus proteins in the sample of cells from the human subject, wherein the cellular protein is selected from a group that comprises p16INK4a, E2F, Ki-67 (MIB-1), MYC protein, CDK4, cyclin-A, cyclin-B, cyclin-E, telomerase-TERC, MCM2 protein, TOP2A protein, heat shock protein 40 (HSP40), heat shock protein 60 (HSP60), heat shock protein 70 (HSP70), CA9/MN protein, laminin 5, laminin proteins, brn-3a, CDK N2 protein, topoisomerase 2A, microsome maintenance proteins-2, micro some maintenance proteins-4, micro some maintenance proteins-5, survivin protein, VEGF protein, p53, RB, p27(kip1), and p21 (waf).

### Claim 16 (depends on 1)

The method of claim 1, wherein the more than one papillomavirus type are selected from a group that comprises high risk HPV types, low risk HPV types, HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, and HPV-68, HPV-6, HPV-11, HPV-42, HPV-43, HPV-44, HPV-53, HPV-54, HPV-55, and HPV-56.

### Claim 17 (depends on 1)

The method of claim 1, wherein
the late dysplasia stage is selected from a group that comprises late stage HPV infection, late stage cervical cell lesion, low grade of squamous intraepithelial lesion (LSIL), high grade of squamous intraepithelial lesion (HSIL), atypical squamous cells of undetermined significance (ASCUS), cervical intraepithelial neoplasm stage 1, 2, 3 (CIN1, CIN2, CIN3), developed cervical cancer, adenocarcinoma, and squamous cell carcinoma (SCC).

### Claim 18 (depends on 1)

The method of claim 1, wherein the sample of cells is obtained from a cervical swab or a cervical scrape.

### Claim 19 (depends on 1)

The method of claim 1, wherein prior to the action of coating with the first coat, coat the portion of the solid surface with a capturing antibody, wherein
the capturing antibody captures the papillomavirus protein in the cell lysate solution.
